Jaypirca, 'Much-Needed' Treatment for CLL and SLL, Approved

Recently approved by the FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Jaypirca “represents a meaningful advance” in treatment, as one expert explained.

Related Keywords

Adam Kittai , Juan Alderuccio , James Cancer Center , Drug Administration , Ohio University Cancer Center , Sylvester Comprehensive Cancer Center , University Of Miami Health System , Miami Health System , Educated Patient , Leukemia , Lymphoma , News ,